Advances and gaps in SARS-CoV-2 infection models
C Muñoz-Fontela, L Widerspick, RA Albrecht… - PLoS …, 2022 - journals.plos.org
The global response to Coronavirus Disease 2019 (COVID-19) is now facing new
challenges such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern …
challenges such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern …
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination
TG Caniels, I Bontjer, K van der Straten, M Poniman… - Science …, 2021 - science.org
Emerging SARS-CoV-2 variants of concern (VOCs) pose a threat to human immunity
induced by natural infection and vaccination. We assessed the recognition of three VOCs (B …
induced by natural infection and vaccination. We assessed the recognition of three VOCs (B …
Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
Abstract The SARS-CoV-2 Omicron variant has very high levels of transmission, is resistant
to neutralization by authorized therapeutic human monoclonal antibodies (mAb) and is less …
to neutralization by authorized therapeutic human monoclonal antibodies (mAb) and is less …
Modeling how antibody responses may determine the efficacy of COVID-19 vaccines
Predicting the efficacy of COVID-19 vaccines would aid vaccine development and usage
strategies, which is of importance given their limited supplies. Here we develop a multiscale …
strategies, which is of importance given their limited supplies. Here we develop a multiscale …
Markers of polyfunctional SARS-CoV-2 antibodies in convalescent plasma
Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but
the antibody characteristics that contribute to efficacy remain poorly understood. This study …
the antibody characteristics that contribute to efficacy remain poorly understood. This study …
A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
Delineating the origins and properties of antibodies elicited by SARS-CoV-2 infection and
vaccination is critical for understanding their benefits and potential shortcomings. Therefore …
vaccination is critical for understanding their benefits and potential shortcomings. Therefore …
Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is
key for translation from promising in vitro results to successful clinical implementation …
key for translation from promising in vitro results to successful clinical implementation …
Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein
The development of small-molecules targeting different components of SARS-CoV-2 is a key
strategy to complement antibody-based treatments and vaccination campaigns in managing …
strategy to complement antibody-based treatments and vaccination campaigns in managing …
Potential anti-SARS-CoV-2 prodrugs activated by phosphorylation and their role in the aged population
The COVID-19 pandemic has flared across every part of the globe and affected populations
from different age groups differently. People aged from 40 to 80 years or older are at an …
from different age groups differently. People aged from 40 to 80 years or older are at an …